Candida krusei infections and fluconazole therapy

Candida species are by far the most common agents of mucosal fungal infection in man. While Candida albicans is the most notorious pathogen in this group, non-albicans species such as Candida krusei are gradually emerging as pathogens of concern, especially in compromised hosts. It is thought that the wide use of the newer triazole drug, fluconazole, in HIV- infected individuals is contributing to this phenomenon. Studies in both humans and animals have now demonstrated prophylactic and therapeutic failure of fluconazole against C. krusei due to increasing resistance of the organism to this azole. Thus, the indiscriminate use of fluconazole, a drug with relatively minimal toxicity and excellent pharmacokinetics, may lead to the development of widespread resistance to this azole among Candida species.published_or_final_versio

Turbidometric evaluation of polyene-azole antagonism in C. albicans

published_or_final_versio

Oral bacteria modulate Candida biofilm formation

published_or_final_versio

Oral Candida infections--a review.

Candida species are the commonest agents of oral mycoses. They cause a variety of diseases including the new variant, erythematous candidosis, which is frequently described in HIV infection. Due to these and other reasons the classification of oral candidosis has been recently revised, and further more new therapeutic regimes have been described. Hence in this article an overview of oral Candida infections is presented with special emphasis on current concepts related to classification and treatment.published_or_final_versio

Variations in germ-tube formation amongst oral Candida albicans isolates from HIV-infected and uninfected individuals

Abstract no. 7published_or_final_versio

Predominant cultivable subgingival microbiota of HIV-infected ethnic Chinese

published_or_final_versio

Chronic hyperplastic candidosis/candidiasis (candidal leukoplakia)

Chronic hyperplastic candidosis/candidiasis (CHC; syn. candidal leukoplakia) is a variant of oral candidosis that typically presents as a white patch on the commissures of the oral mucosa. The major etiologic agent of the disease is the oral fungal pathogen Candida predominantly belonging to Candida albicans, although other systemic co-factors, such as vitamin deficiency and generalized immune suppression, may play a contributory role. Clinically, the lesions are symptomless and regress after appropriate antifungal therapy and correction of underlying nutritional or other deficiencies. If the lesions are untreated, a minor proportion may demonstrate dysplasia and develop into carcinomas. This review outlines the demographic features, etiopathogenesis, immunological features, histopathology, and the role of Candida in the disease process. In the final part of the review, newer molecular biological aspects of the disease are considered together with the management protocols that are currently available, and directions for future research.published_or_final_versio

Salivary immunoglobulin A levels in "rapid" and "slow" plaque formers

published_or_final_versio

Correlation between the cyclin A and p53 gene expression in oral carcinogenesis

published_or_final_versio

The effect of chlorhexidine gluconate on the germ tube formation of Candida albicans and its relatedness to post-antifungal effect

published_or_final_versio